MOLECULAR DETERMINANTS OF THE DEVELOPMENT OF EARLY AND LATE PREECLAMPSIA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the molecular biological aspects of two clinical variants of preeclampsia (early- and late-onset preeclampsia), the specific features of the expression of different molecules involved in the development of preeclampsia, including the concentrations of vascular endothelial growth factor, placental growth factor, vascular endothelial growth factor receptor-1, epidermal growth factor, transforming growth factor-β, vascular cell adhesion molecules, toll-like receptor, serum pentraxin 3, soluble endoglin, and the expressions of different mRNAs.

Full Text

Restricted Access

About the authors

Z. S KHODZHAEVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation

Email: z_khodzhaeva@oparina4.ru
M.D., Ph.D., Professor, Principal Investigator, Department of Maternal-Fetal Medicine 117437, Russia, Moscow, Ac. Oparina str. 4

A. S AKATYEVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation

Email: Akatyevaas@gmail.com
Postgraduate student 117437, Russia, Moscow, Ac. Oparina str. 4

A. M KHOLIN

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation

Email: a_kholin@oparina4.ru
M.D., Research Associate, Department of Maternal Fetal Medicine 117437, Russia, Moscow, Ac. Oparina str. 4

A. D SAFONOVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation

Email: Adsafonova@mail.ru
Postgraduate student 117437, Russia, Moscow, Ac. Oparina str. 4

O. V VAVINA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation

Email: o_vavina@oparina4.ru
Postgraduate student 117437, Russia, Moscow, Ac. Oparina str. 4

K. T MUMINOVA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of the Russian Federation

Email: kamika9l@mail.ru
Graduate 117437, Russia, Moscow, Ac. Oparina str. 4

References

  1. Trogstad L., Magnus P., Stoltenberg C. Pre-eclampsia: risk factors and causal models. Best Pract. Res. Clin. Obstet. Gynaecol. 2011; 25(3): 329-42.
  2. Ghulmiyyah L., Sibai B. Maternal mortality from preeclampsia/eclampsia. Semin. Perinatol. 2012; 36(1): 56-9.
  3. Запорожец Э.Е., Шувалова М.П., Цымлякова Л.М., Фролова О.Г., Огрызко Е.В., Суханова Л.П. Основные показатели деятельности службы охраны здоровья матери и ребенка в Российской Федерации. Статистическая форма 32 за 2012 год. М.: Российское общество акушеров-гинекологов, ФГБУ «НЦАГИП им. В.И. Кулакова» Минздрава России, ФГБУ «ЦНИИОИЗ» Минздрава России; 2013: 48-50, 59-61.
  4. Andersgaard A.B., Acharya G., Mathiesen E.B., Johnsen S.H., Straume B., Øian P. Recurrence and long-term maternal health risks of hypertensive disorders of pregnancy: a population-based study. Am. J. Obstet. Gynecol. 2012; 206(2): 43. e1-8.
  5. Young B., Hacker M.R., Rana S. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Hypertens. Pregnancy. 2012; 31(1): 50-8.
  6. Valensise H., Vasapollo B., Gagliardi G., Novelli G.P. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension. 2008; 52(5): 873-80.
  7. Steegers E.A., von Dadelszen P., Duvekot J.J., Pijnenborg R. Pre-eclampsia. Lancet. 2010; 376(9741): 631-44.
  8. Pijnenborg R., Vercruysse L., Hanssens M., Brosens I. Endovascular trophoblast and preeclampsia: A reassessment. Pregnancy Hypertens. 2011; 1(1): 66-71.
  9. Бурлев В.А., Зайдиева З.С., Ильясова Н.А. Регуляция ангиогенеза гестационного периода (обзор литературы). Проблемы репродукции. 2008; 3: 18-22. // Burlev V.A., Zaydieva Z.S., Ilyasova N.A. Regulyatsiya angiogeneza gestatsionnogo perioda (obzor literaturyi). Problemyi reproduktsii. 2008; 3: 18-22.
  10. Powe C.E., Levine R.J., Karumanchi S.A. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011; 123(24): 2856-69.
  11. Ahmad S., Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 2004; 95: 884-91.
  12. Wikström A.K., Larsson A., Eriksson U.J., Nash P., Nordén-Lindeberg S., Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet. Gynecol. 2007; 109(6): 1368-74.
  13. Kim Y.N., Lee D.S., Jeong D.H., Sung M.S., Kim K.T. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat. Diagn. 2009; 29(5): 464-70.
  14. Wikström A.K., Larsson A., Eriksson U.J., Nash P., Olovsson M. Early postpartum changes in circulating pro- and anti-angiogenic factors in early-onset and late-onset preeclampsia. Acta Obstet. Gynecol. Scand. 2008; 87(2): 146-53.
  15. Myatt L., Clifton R.G., Roberts J.M., Spong C.Y., Hauth J.C., Varner M.W. et al. The utility of uterine artery Doppler velocimetry in prediction of preeclampsia in a low-risk population. Obstet. Gynecol. 2012; 120(4): 815-22.
  16. Odibo A.O., Zhong Y., Goetzinger K.R., Odibo L., Bick J.L., Bower C.R., Nelson D.M. First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of preeclampsia. Placenta. 2011; 32(8): 598-602.
  17. Grill S., Rusterholz C., Zanetti-Dällenbach R., Tercanli S., Holzgreve W., Hahn S., Lapaire O. Potential markers of preeclampsia-a review. Reprod. Biol. Endocrinol. 2009; 7: 70.
  18. Crispi F., Domínguez C., Llurba E., Martín-Gallán P., Cabero L., Gratacós E. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. Am. J. Obstet. Gynecol. 2006; 195(1): 201-7.
  19. Romero R., Nien J.K., Espinoza J., Todem D., Fu W., Chung H. et al. A longitudinal study of angiogenic (placental growth factor) and antiangiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J. Matern. Fetal Neonatal Med. 2008; 21(1): 9-23.
  20. Kenny L.C., Broadhurst D.I., Dunn W., Brown M., North R.A., McCowan L. et al. Screening for pregnancy endpoints consortium. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension. 2010; 56(4): 741-9.
  21. Buhimschi I., Norwitz E.R., Funai E., Richman S., Guller S., Lockwood C.J., Buhimschi I.A. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am. J. Obstet. Gynecol. 2005; 192(3): 734-41.
  22. Sung J.F., Fan X., Dhal S., Dwyer B.K., Jafari A., El-Sayed Y.Y. et al. Decreased circulating soluble Tie2 levels in preeclampsia may result from inhibition of vascular endothelial growth factor (VEGF) signaling. J. Clin. Endocrinol. Metab. 2011; 96(7): E1148-52.
  23. Tripathi R., Rath G., Jain A., Salhan S. Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by preeclampsia. Ann. Anat. 2008; 190(5): 477-89.
  24. Wathén K.A., Ylikorkala O., Andersson S., Alfthan H., Stenman U.H., Vuorela P. Maternal serum endostatin at gestational weeks 16-20 is elevated in subsequent pre-eclampsia but not in intrauterine growth retardation. Acta Obstet. Gynecol. Scand. 2009; 88(5): 593-8.
  25. Wikström A.K., Larsson A., Akerud H., Olovsson M. Increased circulating levels of the antiangiogenic factor endostatin in early-onset but not late-onset preeclampsia. Reprod. Sci. 2009; 16(10): 995-1000.
  26. Gauster M., Moser G., Orendi K., Huppertz B. Factors involved in regulating trophoblast fusion: potential role in the development of preeclampsia. Placenta. 2009; 30(Suppl. A): S49-54.
  27. Peraçoli M.T., Menegon F.T., Borges V.T., de Araujo Costa R.A., Thomazini-Santos I.A., Peraçoli J.C. Platelet aggregation and TGF-beta(1) plasma levels in pregnant women with preeclampsia. J. Reprod. Immunol. 2008; 79(1): 79-84.
  28. Imudia A.N., Kilburn B.A., Petkova A., Edwin S.S., Romero R., Armant D.R. Expression of heparin-binding EGF-like growth factor in term chorionic villous explants and its role in trophoblast survival. Placenta. 2008; 29(9): 784-9.
  29. Stanczuk G.A., Mccoy M.J., Hutchinson I.V., Sibanda E.N. The genetic predisposition to produce high levels of TGF-beta1 impacts on the severity of eclampsia/pre-eclampsia. Acta Obstet. Gynecol. Scand. 2007; 86(8): 903-8.
  30. Kusanovic J.P., Romero R., Chaiworapongsa T., Erez O., Mittal P., Vaisbuch E. et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J. Matern. Fetal Neonatal Med. 2009; 22(11): 1021-38.
  31. Baumann M.U., Bersinger N.A., Mohaupt M.G., Raio L., Gerber S., Surbek D.V. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset pre-eclampsia. Am. J. Obstet. Gynecol. 2008; 199(3): 266. e1-6
  32. Stepan H., Geipel A., Schwarz F., Krämer T., Wessel N., Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am. J. Obstet. Gynecol. 2008; 198(2): 175. e1-6.
  33. Oggé G., Romero R., Chaiworapongsa T., Gervasi M.T., Pacora P., Erez O. et al. Leukocytes of pregnant women with small-for-gestational age neonates have a different phenotypic and metabolic activity from those of women with preeclampsia. J. Matern. Fetal Neonatal Med. 2010; 23(6): 476-87.
  34. Vitoratos N., Economou E., Iavazzo C., Panoulis K., Creatsas G. Maternal serum levels of TNF-alpha and IL-6 long after delivery in preeclamptic and normotensive pregnant women. Mediators Inflamm. 2010; 2010: 908649.
  35. Oyama R. The relationship between the level of expression of intracellular adhesion molecule-1 in placenta and onset of preeclampsia. J. Obstet. Gynaecol. Res. 2001; 27(3): 147-54.
  36. Molvarec A., Jermendy A., Kovács M., Prohászka Z., Rigó J.Jr. Toll-like receptor 4 gene polymorphisms and preeclampsia: lack of association in a Caucasian population. Hypertens. Res. 2008; 31(5): 859-64.
  37. Van Rijn B.B., Franx A., Steegers E.A., de Groot C.J., Bertina R.M., Pasterkamp G. et al. Maternal TLR4 and NOD2 gene variants, pro-inflammatory phenotype and susceptibility to early-onset preeclampsia and HELLP syndrome. PLoS One. 2008; 3(4): e1865.
  38. Vaughan J.E., Walsh S.W. Activation of NF-xB in placentas of women with preeclampsia. Hypertens. Pregnancy. 2012; 31(2): 243-51.
  39. Akolekar R., Casagrandi D., Livanos P., Tetteh A., Nicolaides K.H. Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat. Diagn. 2009; 29(10): 934-8.
  40. Cetin I., Cozzi V., Papageorghiou A.T., Maina V., Montanelli A., Garlanda C., Thilaganathan B. First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction. Acta Obstet. Gynecol. Scand. 2009; 88(7): 846-9.
  41. Wikstrom A.K., Nash P., Eriksson U.J., Olovsson M.H. Evidence of increased oxidative stress and a change in the plasminogen activator inhibitor (PAI)-1 to PAI-2 ratio in early-onset but not late-onset preeclampsia. Am. J. Obstet. Gynecol. 2009; 201(6): 597. e591-8.
  42. Morgan J.A., Bombell S., McGuire W. Association of plasminogen activator inhibitor-type 1 (-675 4G/5G) polymorphism with pre-eclampsia: systematic review. PLoS One. 2013; 8(2): e56907.
  43. Gupta A.K., Gebhardt S., Hillermann R., Holzgreve W., Hahn S. Analysis of plasma elastase levels in early and late onset preeclampsia. Arch. Gynecol. Obstet. 2006; 273(4): 239-42.
  44. Vaisbuch E., Mazaki-Tovi S., Kusanovic J.P., Erez O., Than N.G., Kim S.K. et al. Retinol binding protein 4: an adipokine associated with intra-amniotic infection/inflammation. J. Matern. Fetal Neonatal Med. 2010; 23(2): 111-9.
  45. Masuyama H., Segawa T., Sumida Y., Masumoto A., Inoue S., Akahori Y., Hiramatsu Y. Different profiles of circulating angiogenic factors and adi-pocytokines between early- and late-onset pre-eclampsia. Br. J. Obstet. Gynaecol. 2010; 117(3): 314-20.
  46. Fu G., Brkic J., Hayder H., Peng C. MicroRNAs in human placental development and pregnancy complications. Int. J. Mol. Sci. 2013; 14(3): 5519-44.
  47. Li P., Guo W., Du L., Zhao J., Wang Y., Liu L. et al. MicroRNA-29b contributes to pre-eclampsia through its effects on apoptosis, invasion and angiogenesis of trophoblast cells. Clin. Sci. 2013; 124: 27-40.
  48. Wang W., Feng L., Zhang H., Hachy S., Satohisa S., Laurent L.C. et al. Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, _20a, and _20b) that target ephrin-B2 and EPHB4 in human placenta. J. Clin. Endocrinol. Metab. 2012; 97: E1051-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies